Get to know our clinical trials
Randomized, open-label, multicenter clinical trial of xaluritamig vs. cabazitaxel or a second androgen receptor-targeted therapy in subjects with metastatic castration-resistant prostate cancer.
THIS STUDY IS BEING CONDUCTED TO LEARN MORE ABOUT THE SAFETY AND EFFICACY OF XALURITAMIG COMPARED TO ALREADY APPROVED STANDARD TREATMENTS IN PATIENTS WITH PROSTATE CANCER THAT HAS SPREAD TO OTHER PARTS OF THE BODY (ALSO CALLED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER [MCRPC]) WHO HAVE ALREADY BEEN TREATED WITH CHEMOTHERAPY.
Technical Summary
- RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 3 STUDY OF XALURITAMIG VS. CABAZITAXEL OR A SECOND ANDROGEN RECEPTOR-TARGETED THERAPY IN SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH CHEMOTHERAPY
- Code EudraCT: 2024-513968-25
- Protocol number: 20230005
- Promoter: Amgen, S.A.
- Molecule/Drug: xaluritamig
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.